Pub Date : 2025-11-13DOI: 10.1080/03009742.2025.2580769
N Choma, H Kumaresan, E Haury, S Ifteqar
{"title":"Recombinant adjuvant zoster vaccine-associated acute mucocutaneous toxicity.","authors":"N Choma, H Kumaresan, E Haury, S Ifteqar","doi":"10.1080/03009742.2025.2580769","DOIUrl":"https://doi.org/10.1080/03009742.2025.2580769","url":null,"abstract":"","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-2"},"PeriodicalIF":2.1,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145506720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-10DOI: 10.1080/03009742.2025.2573532
S A Provan, H Berner-Hammer, A L Kleppang
Objectives: The Revised Fibromyalgia Impact Questionnaire (FIQ-R) is a composite questionnaire covering key domains of fibromyalgia disease burden. This study aimed to translate the FIQ-R into Norwegian, to assess face, content, and criterion validity, and to evaluate the psychometric properties of the Norwegian FIQ-R using Rasch analysis, in a sample of adults with fibromyalgia.
Method: The FIQ-R was translated into Norwegian following established methodology in collaboration with patient research partners. Participants attending a patient education session for people with chronic musculoskeletal pain were asked to complete, anonymously, the translated FIQ-R, Fibromyalgia Self-reported Diagnostic Criteria (FSDC), 36-item Short Form Health Survey (SF-36), and Modified Health Assessment Questionnaire (MHAQ). Fibromyalgia cases were identified according to the FSDC. Correlations between FIQ-R, MHAQ, and SF-36 were calculated. Rasch analysis was performed.
Results: In total, 241 participants (96.3% female) were classified as having fibromyalgia according to the FSDC. The translated FIQ-R had acceptable face and content validity. The correlation coefficients were moderate between FIQ-R and SF-36, and strong between FIQ-R and MHAQ. The FIQ-R formed a multidimensional scale, indicating two subscales: FIQ-R function and FIQ-R symptoms. Both subscales showed reversed threshold ordering and were consequently collapsed into five and four response categories, respectively. The resulting subscales were found to have good reliability and targeting.
Conclusion: Owing to the lack of unidimensionality in the FIQ-R, it is recommended that both clinical and research applications rely on subscale scores rather than a total score.
{"title":"Psychometric evaluation of the Norwegian version of the Revised Fibromyalgia Impact Questionnaire.","authors":"S A Provan, H Berner-Hammer, A L Kleppang","doi":"10.1080/03009742.2025.2573532","DOIUrl":"https://doi.org/10.1080/03009742.2025.2573532","url":null,"abstract":"<p><strong>Objectives: </strong>The Revised Fibromyalgia Impact Questionnaire (FIQ-R) is a composite questionnaire covering key domains of fibromyalgia disease burden. This study aimed to translate the FIQ-R into Norwegian, to assess face, content, and criterion validity, and to evaluate the psychometric properties of the Norwegian FIQ-R using Rasch analysis, in a sample of adults with fibromyalgia.</p><p><strong>Method: </strong>The FIQ-R was translated into Norwegian following established methodology in collaboration with patient research partners. Participants attending a patient education session for people with chronic musculoskeletal pain were asked to complete, anonymously, the translated FIQ-R, Fibromyalgia Self-reported Diagnostic Criteria (FSDC), 36-item Short Form Health Survey (SF-36), and Modified Health Assessment Questionnaire (MHAQ). Fibromyalgia cases were identified according to the FSDC. Correlations between FIQ-R, MHAQ, and SF-36 were calculated. Rasch analysis was performed.</p><p><strong>Results: </strong>In total, 241 participants (96.3% female) were classified as having fibromyalgia according to the FSDC. The translated FIQ-R had acceptable face and content validity. The correlation coefficients were moderate between FIQ-R and SF-36, and strong between FIQ-R and MHAQ. The FIQ-R formed a multidimensional scale, indicating two subscales: FIQ-R function and FIQ-R symptoms. Both subscales showed reversed threshold ordering and were consequently collapsed into five and four response categories, respectively. The resulting subscales were found to have good reliability and targeting.</p><p><strong>Conclusion: </strong>Owing to the lack of unidimensionality in the FIQ-R, it is recommended that both clinical and research applications rely on subscale scores rather than a total score.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145482878","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-10DOI: 10.1080/03009742.2025.2550133
J M van Dongen, L Bernaers, C A Wagenaar, M van der Leeden, F Turkstra, M Boers, H van Middendorp, Pjm Weijs, D van Schaardenburg, W Walrabenstein
Objective: To evaluate the cost-effectiveness of the 'Plants for Joints' intervention for rheumatoid arthritis (RA) and metabolic syndrome-associated osteoarthritis (MSOA) patients over 16 weeks.
Method: Data from two randomized controlled trials were analysed. The first included 77 RA patients (intervention = 40; control = 37) and the second 64 MSOA patients (intervention = 32; control = 32). The intervention comprised a 16 week lifestyle programme including a whole-food plant-based diet, exercise, and stress management; control participants received usual care. Data from both trials were analysed together and separately. Costs were measured from societal and healthcare perspectives. Effects were expressed in quality-adjusted life-years (QALYs).
Results: The intervention cost €886/patient. Intervention group participants gained more QALYs than the control group (0.009; 95% confidence interval -0.004 to 0.023), equivalent to 3.3 additional days in 'perfect health' (0.009 × 365). Healthcare costs were higher in the intervention group, while societal costs were lower. None of these differences was statistically significant. From a societal perspective, the intervention had a moderate to high probability of being cost-effective compared with usual care, while the probability was low from a healthcare perspective. Stratified analyses indicated that the probability of cost-effectiveness was higher in RA than in MSOA patients. This difference became less pronounced after excluding outliers.
Conclusion: The Plants for Joints intervention demonstrated a relatively high probability of cost-effectiveness from a societal perspective, although this was lower from a healthcare perspective. If these benefits are sustained in the long term, this intervention may reduce the disease and economic burden of arthritic conditions.
{"title":"A multidisciplinary lifestyle programme for patients with rheumatoid arthritis and metabolic syndrome-associated osteoarthritis: economic evaluation alongside the 'Plants for Joints' randomized controlled trials.","authors":"J M van Dongen, L Bernaers, C A Wagenaar, M van der Leeden, F Turkstra, M Boers, H van Middendorp, Pjm Weijs, D van Schaardenburg, W Walrabenstein","doi":"10.1080/03009742.2025.2550133","DOIUrl":"https://doi.org/10.1080/03009742.2025.2550133","url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the cost-effectiveness of the 'Plants for Joints' intervention for rheumatoid arthritis (RA) and metabolic syndrome-associated osteoarthritis (MSOA) patients over 16 weeks.</p><p><strong>Method: </strong>Data from two randomized controlled trials were analysed. The first included 77 RA patients (intervention = 40; control = 37) and the second 64 MSOA patients (intervention = 32; control = 32). The intervention comprised a 16 week lifestyle programme including a whole-food plant-based diet, exercise, and stress management; control participants received usual care. Data from both trials were analysed together and separately. Costs were measured from societal and healthcare perspectives. Effects were expressed in quality-adjusted life-years (QALYs).</p><p><strong>Results: </strong>The intervention cost €886/patient. Intervention group participants gained more QALYs than the control group (0.009; 95% confidence interval -0.004 to 0.023), equivalent to 3.3 additional days in 'perfect health' (0.009 × 365). Healthcare costs were higher in the intervention group, while societal costs were lower. None of these differences was statistically significant. From a societal perspective, the intervention had a moderate to high probability of being cost-effective compared with usual care, while the probability was low from a healthcare perspective. Stratified analyses indicated that the probability of cost-effectiveness was higher in RA than in MSOA patients. This difference became less pronounced after excluding outliers.</p><p><strong>Conclusion: </strong>The Plants for Joints intervention demonstrated a relatively high probability of cost-effectiveness from a societal perspective, although this was lower from a healthcare perspective. If these benefits are sustained in the long term, this intervention may reduce the disease and economic burden of arthritic conditions.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-14"},"PeriodicalIF":2.1,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145482760","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-10DOI: 10.1080/03009742.2025.2580770
G Kenar Artin, H Yarkan Tugsal, B Akin, P Cetin, I Sari, N Akkoc
Objective: The aim of the study was to assess the reliability of using the iPhone's built-in Compass application for measuring cervical rotation (CR) degrees in patients with ankylosing spondylitis (AS), compared to traditional methods using an inclinometer and a universal goniometer.
Method: Patients diagnosed with AS and receiving care at our rheumatology outpatient clinic were enrolled in this study. Two examiners measured CR using the iPhone 4 Compass application, an inclinometer, and a universal goniometer. Each measurement was performed twice. Intrarater and interrater reliability were assessed using intraclass correlation coefficients (ICCs), while agreement between methods was analysed by the Bland-Altman method.
Results: The study sample included 30 AS patients (73% male). Excellent intrarater and interrater reliability were observed across all three measurement methods in the entire sample. Bland-Altman analysis showed good agreement between the iPhone and inclinometer, with a mean difference (bias) of -5.6 for Examiner 1 [95% confidence interval (CI) -7.6 to -3.6] and -6.3 for Examiner 2 (95% CI -8.8 to -3.8). The mean differences between the iPhone and universal goniometer measurements were 2.3 for Examiner 1 (95% CI -0.4 to 5.2) and 4.1 for Examiner 2. Similarly, between the universal goniometer and inclinometer, mean differences were -8.0 for Examiner 1 (95% CI -11.2 to -4.8) and -10.4 for Examiner 2.
Conclusion: Through the integration of everyday smartphone technology for clinical use, the iPhone Compass application can be considered a practical and accessible tool for measuring CR in patients with AS, offering potential benefits for clinical practice.
目的:本研究的目的是评估使用iPhone内置的Compass应用程序测量强直性脊柱炎(AS)患者颈椎旋转(CR)度的可靠性,与使用倾角仪和通用角度仪的传统方法相比。方法:诊断为AS并在我们的风湿病门诊接受治疗的患者被纳入本研究。两名检查人员使用iPhone 4 Compass应用程序、倾斜仪和通用倾斜仪测量了CR。每次测量进行两次。采用分类内相关系数(ICCs)评估分类内和分类间的信度,采用Bland-Altman方法分析方法间的一致性。结果:研究样本包括30例AS患者(73%为男性)。在整个样本中,所有三种测量方法都观察到出色的内部和内部可靠性。Bland-Altman分析显示iPhone和倾角仪之间的一致性很好,主考官1的平均差异(偏差)为-5.6[95%置信区间(CI) -7.6至-3.6],主考官2的平均差异(偏差)为-6.3 (95% CI -8.8至-3.8)。iPhone和通用测角仪测量值之间的平均差异对于考官1为2.3 (95% CI -0.4至5.2),对于考官2为4.1。同样,在万能测角仪和倾角仪之间,审查员1的平均差异为-8.0 (95% CI为-11.2至-4.8),审查员2的平均差异为-10.4。结论:通过整合日常智能手机技术用于临床使用,iPhone Compass应用程序可以被认为是测量AS患者CR的实用且易于访问的工具,为临床实践提供了潜在的好处。
{"title":"Assessing cervical rotation in ankylosing spondylitis: iPhone Compass versus traditional tools.","authors":"G Kenar Artin, H Yarkan Tugsal, B Akin, P Cetin, I Sari, N Akkoc","doi":"10.1080/03009742.2025.2580770","DOIUrl":"https://doi.org/10.1080/03009742.2025.2580770","url":null,"abstract":"<p><strong>Objective: </strong>The aim of the study was to assess the reliability of using the iPhone's built-in Compass application for measuring cervical rotation (CR) degrees in patients with ankylosing spondylitis (AS), compared to traditional methods using an inclinometer and a universal goniometer.</p><p><strong>Method: </strong>Patients diagnosed with AS and receiving care at our rheumatology outpatient clinic were enrolled in this study. Two examiners measured CR using the iPhone 4 Compass application, an inclinometer, and a universal goniometer. Each measurement was performed twice. Intrarater and interrater reliability were assessed using intraclass correlation coefficients (ICCs), while agreement between methods was analysed by the Bland-Altman method.</p><p><strong>Results: </strong>The study sample included 30 AS patients (73% male). Excellent intrarater and interrater reliability were observed across all three measurement methods in the entire sample. Bland-Altman analysis showed good agreement between the iPhone and inclinometer, with a mean difference (bias) of -5.6 for Examiner 1 [95% confidence interval (CI) -7.6 to -3.6] and -6.3 for Examiner 2 (95% CI -8.8 to -3.8). The mean differences between the iPhone and universal goniometer measurements were 2.3 for Examiner 1 (95% CI -0.4 to 5.2) and 4.1 for Examiner 2. Similarly, between the universal goniometer and inclinometer, mean differences were -8.0 for Examiner 1 (95% CI -11.2 to -4.8) and -10.4 for Examiner 2.</p><p><strong>Conclusion: </strong>Through the integration of everyday smartphone technology for clinical use, the iPhone Compass application can be considered a practical and accessible tool for measuring CR in patients with AS, offering potential benefits for clinical practice.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-7"},"PeriodicalIF":2.1,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145482768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-06DOI: 10.1080/03009742.2025.2576966
A Pugliesi, Hvrr Nourani, L C Pires, L H Hotta, Lsf de Carvalho, Jrm Souza, M Barros Bertolo
{"title":"Myocardial strain in rheumatoid arthritis without traditional cardiovascular risk factors: an exploratory analysis.","authors":"A Pugliesi, Hvrr Nourani, L C Pires, L H Hotta, Lsf de Carvalho, Jrm Souza, M Barros Bertolo","doi":"10.1080/03009742.2025.2576966","DOIUrl":"https://doi.org/10.1080/03009742.2025.2576966","url":null,"abstract":"","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-3"},"PeriodicalIF":2.1,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145452944","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-06DOI: 10.1080/03009742.2025.2576958
D Nakagomi, S Kubota, S Hanai
{"title":"Limit of the detection of hip joint synovitis using ultrasound in a patient with polymyalgia rheumatica.","authors":"D Nakagomi, S Kubota, S Hanai","doi":"10.1080/03009742.2025.2576958","DOIUrl":"https://doi.org/10.1080/03009742.2025.2576958","url":null,"abstract":"","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-2"},"PeriodicalIF":2.1,"publicationDate":"2025-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145452873","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-05DOI: 10.1080/03009742.2025.2570588
A Glasin, C Svensson, H Jonasson, T Strömberg, P Eriksson, H Zachrisson, C Sjöwall
Objective: Cardiovascular disease (CVD) is a major contributor to organ damage and premature death in patients with systemic lupus erythematosus (SLE). Traditional risk factors do not fully explain the accelerated atherosclerosis or increased CVD risk. Impaired microcirculation and increased intima-media thickness (IMT) may represent early signs of vascular disease. We performed a 3 year follow-up of well-characterized patients with SLE to identify predictors of atherosclerotic plaque progression and accrued organ damage.
Method: Fifty-seven patients (50 females) were assessed twice (3 years apart) using an extended ultrasound protocol with high-frequency ultrasound (HFUS) to assess IMT and occurrence of atherosclerotic plaques. Microcirculation was assessed via forearm microcirculatory peak oxygen saturation after induced ischaemia (OxyP).
Results: At the 3 year follow-up, atherosclerotic plaques were observed in 29/57 patients (50.9%), and progression of plaques was seen in 27 (47.4%). Patients prescribed hydroxychloroquine at follow-up showed significantly less plaque progression (p = 0.045). In multivariable logistic regression analysis, only hydroxychloroquine use remained a statistically significant predictor of less atherosclerotic plaque progression (B = -2.5, p = 0.047). The IMT of common carotid arteries increased significantly in patients who showed progression of atherosclerotic plaques (p = 0.04). OxyP was not significantly associated with either plaque progression or damage accrual.
Conclusion: Despite quiescent disease state, atherosclerosis progresses over time in patients with SLE. Our data support the use of surveillance with HFUS for assessing CVD risk. Continuous use of hydroxychloroquine protected against atherosclerotic plaque progression and should be offered to all patients with SLE, unless contraindicated.
目的:心血管疾病(CVD)是系统性红斑狼疮(SLE)患者器官损伤和过早死亡的主要原因。传统的危险因素不能完全解释动脉粥样硬化加速或心血管疾病风险增加。微循环受损和内膜-中膜厚度(IMT)增加可能是血管疾病的早期征兆。我们对特征明确的SLE患者进行了为期3年的随访,以确定动脉粥样硬化斑块进展和累积器官损伤的预测因素。方法:采用高频超声(HFUS)对57例患者(50例女性)进行两次(间隔3年)扩展超声检查,以评估IMT和动脉粥样硬化斑块的发生。通过诱导缺血后前臂微循环峰值血氧饱和度(OxyP)评估微循环。结果:在3年随访中,57例患者中有29例(50.9%)出现动脉粥样硬化斑块,27例(47.4%)出现斑块进展。随访时服用羟氯喹的患者斑块进展明显减少(p = 0.045)。在多变量logistic回归分析中,只有羟氯喹的使用仍然是动脉粥样硬化斑块进展较少的统计学显著预测因子(B = -2.5, p = 0.047)。动脉粥样硬化斑块进展的患者颈总动脉IMT显著升高(p = 0.04)。氧合蛋白与斑块进展或损伤均无显著相关性。结论:尽管SLE患者处于静止状态,但动脉粥样硬化会随着时间的推移而发展。我们的数据支持使用HFUS监测来评估CVD风险。持续使用羟氯喹可防止动脉粥样硬化斑块进展,所有SLE患者均应使用羟氯喹,除非有禁忌症。
{"title":"Progression of atherosclerotic plaques over 3 years in patients with systemic lupus erythematosus is inversely associated with continuous hydroxychloroquine treatment.","authors":"A Glasin, C Svensson, H Jonasson, T Strömberg, P Eriksson, H Zachrisson, C Sjöwall","doi":"10.1080/03009742.2025.2570588","DOIUrl":"https://doi.org/10.1080/03009742.2025.2570588","url":null,"abstract":"<p><strong>Objective: </strong>Cardiovascular disease (CVD) is a major contributor to organ damage and premature death in patients with systemic lupus erythematosus (SLE). Traditional risk factors do not fully explain the accelerated atherosclerosis or increased CVD risk. Impaired microcirculation and increased intima-media thickness (IMT) may represent early signs of vascular disease. We performed a 3 year follow-up of well-characterized patients with SLE to identify predictors of atherosclerotic plaque progression and accrued organ damage.</p><p><strong>Method: </strong>Fifty-seven patients (50 females) were assessed twice (3 years apart) using an extended ultrasound protocol with high-frequency ultrasound (HFUS) to assess IMT and occurrence of atherosclerotic plaques. Microcirculation was assessed via forearm microcirculatory peak oxygen saturation after induced ischaemia (OxyP).</p><p><strong>Results: </strong>At the 3 year follow-up, atherosclerotic plaques were observed in 29/57 patients (50.9%), and progression of plaques was seen in 27 (47.4%). Patients prescribed hydroxychloroquine at follow-up showed significantly less plaque progression (p = 0.045). In multivariable logistic regression analysis, only hydroxychloroquine use remained a statistically significant predictor of less atherosclerotic plaque progression (B = -2.5, p = 0.047). The IMT of common carotid arteries increased significantly in patients who showed progression of atherosclerotic plaques (p = 0.04). OxyP was not significantly associated with either plaque progression or damage accrual.</p><p><strong>Conclusion: </strong>Despite quiescent disease state, atherosclerosis progresses over time in patients with SLE. Our data support the use of surveillance with HFUS for assessing CVD risk. Continuous use of hydroxychloroquine protected against atherosclerotic plaque progression and should be offered to all patients with SLE, unless contraindicated.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145445708","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-04DOI: 10.1080/03009742.2025.2572885
S Fukui, K Ichinose, H Ide, T Uchida, T Shimizu, M Umeda, R Sumiyoshi, T Koga, S-Y Kawashiri, N Iwamoto, T Origuchi, S Omura, D Nakagomi, Y Abe, M Wada, N Takizawa, A Nomura, Y Kukida, N Kondo, Y Yamano, H Takagi, K Endo, S Hirata, N Azuma, T Takeuchi, K Kamada, R Yanai, Y Matsuo, Y Shimojima, R Nishioka, R Okazaki, T Takata, M Moriyama, A Takatani, Y Miyawaki, T Shirai, H Dobashi, T Ito, I Matsumoto, T Takada, T Ito-Ihara, T Kida, N Yajima, T Kawaguchi, Y Kawahito, A Kawakami
Objectives: To evaluate the relationship between anti-neutrophil cytoplasmic antibody (ANCA) positivity and the disease characteristics, treatment, and prognosis of eosinophilic granulomatosis with polyangiitis (EGPA).
Method: We conducted a retrospective cohort study of patients with new-onset or severely relapsing ANCA-associated vasculitis, enrolled in the J-CANVAS registry. The clinical characteristics at baseline, treatments, and prognoses of ANCA-positive and ANCA-negative patients were assessed.
Results: Three patients with positive proteinase-3 ANCA were excluded, and 166 patients with EGPA (new onset, 159; severe relapse, seven) were included. Sixty-two patients were myeloperoxidase (MPO)-ANCA positive and 104 patients were negative. No differences in age or sex were observed between the two groups. The MPO-ANCA-positive group had significantly more frequent mucous membrane and eye involvement, more frequent renal involvement, higher total Birmingham Vasculitis Activity Score, higher neutrophil counts, and higher C-reactive protein levels at baseline. Although rituximab was administered more frequently in the MPO-ANCA-positive group, no other differences in treatment were found. Both groups had comparable estimated glomerular filtration rates and prednisolone doses at weeks 24 and 48. The incidence rates of severe relapse, minor relapse, and serious infectious diseases were comparable. Cox regression analysis revealed that MPO-ANCA positivity was not a significant factor in serious infectious diseases and relapse.
Conclusion: Patients with MPO-ANCA-positive EGPA demonstrated different baseline clinical characteristics from MPO-ANCA-negative patients. However, subsequent relapses and serious infectious diseases were comparable.
{"title":"Myeloperoxidase-anti-neutrophil cytoplasmic antibody positivity and disease characteristics, treatment, and prognosis in eosinophilic granulomatosis with polyangiitis.","authors":"S Fukui, K Ichinose, H Ide, T Uchida, T Shimizu, M Umeda, R Sumiyoshi, T Koga, S-Y Kawashiri, N Iwamoto, T Origuchi, S Omura, D Nakagomi, Y Abe, M Wada, N Takizawa, A Nomura, Y Kukida, N Kondo, Y Yamano, H Takagi, K Endo, S Hirata, N Azuma, T Takeuchi, K Kamada, R Yanai, Y Matsuo, Y Shimojima, R Nishioka, R Okazaki, T Takata, M Moriyama, A Takatani, Y Miyawaki, T Shirai, H Dobashi, T Ito, I Matsumoto, T Takada, T Ito-Ihara, T Kida, N Yajima, T Kawaguchi, Y Kawahito, A Kawakami","doi":"10.1080/03009742.2025.2572885","DOIUrl":"10.1080/03009742.2025.2572885","url":null,"abstract":"<p><strong>Objectives: </strong>To evaluate the relationship between anti-neutrophil cytoplasmic antibody (ANCA) positivity and the disease characteristics, treatment, and prognosis of eosinophilic granulomatosis with polyangiitis (EGPA).</p><p><strong>Method: </strong>We conducted a retrospective cohort study of patients with new-onset or severely relapsing ANCA-associated vasculitis, enrolled in the J-CANVAS registry. The clinical characteristics at baseline, treatments, and prognoses of ANCA-positive and ANCA-negative patients were assessed.</p><p><strong>Results: </strong>Three patients with positive proteinase-3 ANCA were excluded, and 166 patients with EGPA (new onset, 159; severe relapse, seven) were included. Sixty-two patients were myeloperoxidase (MPO)-ANCA positive and 104 patients were negative. No differences in age or sex were observed between the two groups. The MPO-ANCA-positive group had significantly more frequent mucous membrane and eye involvement, more frequent renal involvement, higher total Birmingham Vasculitis Activity Score, higher neutrophil counts, and higher C-reactive protein levels at baseline. Although rituximab was administered more frequently in the MPO-ANCA-positive group, no other differences in treatment were found. Both groups had comparable estimated glomerular filtration rates and prednisolone doses at weeks 24 and 48. The incidence rates of severe relapse, minor relapse, and serious infectious diseases were comparable. Cox regression analysis revealed that MPO-ANCA positivity was not a significant factor in serious infectious diseases and relapse.</p><p><strong>Conclusion: </strong>Patients with MPO-ANCA-positive EGPA demonstrated different baseline clinical characteristics from MPO-ANCA-negative patients. However, subsequent relapses and serious infectious diseases were comparable.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-9"},"PeriodicalIF":2.1,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145439059","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-04DOI: 10.1080/03009742.2025.2566542
S J Choi, S Lee, S Park, M Park, S W Choi, D-H Lim
Objective: Systemic lupus erythematosus (SLE) is associated with increased cancer risk. However, the patterns of cancer incidence remain unclear. This study aimed to evaluate the cancer risk in patients with SLE.
Method: This population-based cohort study identified 24 241 patients with newly diagnosed SLE between 2004 and 2020 using Korean National Health Insurance Service data. Patients were followed up until cancer diagnosis, death, or December 2021. Standardized incidence ratios (SIRs) were calculated to compare cancer risk between patients with SLE and the general population. Subgroup analyses were performed based on the age at diagnosis, follow-up duration, and use of immunosuppressive agents.
Results: Patients with SLE had higher risks of overall [SIR 3.3, 95% confidence interval (CI) 3.2-3.4], solid (SIR 3.1, 95% CI 3.0-3.2), and haematological (SIR 9.8, 95% CI 8.9-10.9) cancers compared with the general population. Among solid cancers, liver cancer had the highest risk, followed by ovarian cancer. The relative cancer risk peaked among patients aged 20-39 years (SIR 4.9, 95% CI 4.6-5.2) and during the first year after diagnosis (SIR 4.7, 95% CI 4.3-5.1). The SIRs for haematological, cervical, and lung cancers in cyclophosphamide-treated patients were higher than those for the corresponding cancers in the overall SLE population.
Conclusion: Patients with SLE have increased cancer risk compared with the general population. Increased relative cancer risk is associated with younger age, first year post-diagnosis, and cyclophosphamide treatment.
目的:系统性红斑狼疮(SLE)与癌症风险增加相关。然而,癌症发病率的模式仍不清楚。本研究旨在评估SLE患者的癌症风险。方法:这项基于人群的队列研究使用韩国国民健康保险服务的数据,确定了2004年至2020年间24241例新诊断的SLE患者。对患者进行随访,直到癌症诊断、死亡或2021年12月。计算标准化发病率(SIRs)来比较SLE患者和一般人群之间的癌症风险。根据诊断时的年龄、随访时间和免疫抑制剂的使用情况进行亚组分析。结果:与一般人群相比,SLE患者总体(SIR 3.3, 95%可信区间(CI) 3.2-3.4)、实体(SIR 3.1, 95% CI 3.0-3.2)和血液学(SIR 9.8, 95% CI 8.9-10.9)癌症的风险更高。在实体癌中,肝癌的风险最高,其次是卵巢癌。相对癌症风险在20-39岁(SIR 4.9, 95% CI 4.6-5.2)和诊断后第一年(SIR 4.7, 95% CI 4.3-5.1)的患者中达到峰值。环磷酰胺治疗患者的血液病、宫颈癌和肺癌的SIRs高于整体SLE人群中相应癌症的SIRs。结论:与一般人群相比,SLE患者患癌症的风险增加。增加的相对癌症风险与年龄较小、诊断后第一年和环磷酰胺治疗有关。
{"title":"Cancer risk in patients with systemic lupus erythematosus: a population-based cohort study in the Republic of Korea 2004-2021.","authors":"S J Choi, S Lee, S Park, M Park, S W Choi, D-H Lim","doi":"10.1080/03009742.2025.2566542","DOIUrl":"https://doi.org/10.1080/03009742.2025.2566542","url":null,"abstract":"<p><strong>Objective: </strong>Systemic lupus erythematosus (SLE) is associated with increased cancer risk. However, the patterns of cancer incidence remain unclear. This study aimed to evaluate the cancer risk in patients with SLE.</p><p><strong>Method: </strong>This population-based cohort study identified 24 241 patients with newly diagnosed SLE between 2004 and 2020 using Korean National Health Insurance Service data. Patients were followed up until cancer diagnosis, death, or December 2021. Standardized incidence ratios (SIRs) were calculated to compare cancer risk between patients with SLE and the general population. Subgroup analyses were performed based on the age at diagnosis, follow-up duration, and use of immunosuppressive agents.</p><p><strong>Results: </strong>Patients with SLE had higher risks of overall [SIR 3.3, 95% confidence interval (CI) 3.2-3.4], solid (SIR 3.1, 95% CI 3.0-3.2), and haematological (SIR 9.8, 95% CI 8.9-10.9) cancers compared with the general population. Among solid cancers, liver cancer had the highest risk, followed by ovarian cancer. The relative cancer risk peaked among patients aged 20-39 years (SIR 4.9, 95% CI 4.6-5.2) and during the first year after diagnosis (SIR 4.7, 95% CI 4.3-5.1). The SIRs for haematological, cervical, and lung cancers in cyclophosphamide-treated patients were higher than those for the corresponding cancers in the overall SLE population.</p><p><strong>Conclusion: </strong>Patients with SLE have increased cancer risk compared with the general population. Increased relative cancer risk is associated with younger age, first year post-diagnosis, and cyclophosphamide treatment.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145439054","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-11-04DOI: 10.1080/03009742.2025.2562676
P Parmanne, A Kuuliala, A Häme, R Luosujärvi, M Leirisalo-Repo, K Kuuliala
Objective: Raynaud's phenomenon (RP) is a common symptom and may be an early sign of systemic sclerosis (SSc). To identify biomarkers distinguishing whether RP is associated with definitive SSc, we used phosphospecific flow cytometry to measure phosphorylated (p) signalling molecules [signal transducers and activators of transcription (pSTAT3, pSTAT6, pSTAT4), pSmad2/3, nuclear factor-κB (pNF-κB)] in peripheral blood leucocytes of RP patients undergoing nailfold videocapillaroscopy.
Method: Leucocyte subsets (CD14+ monocytes, CD4+ and CD8+ T cells, CD19+ B cells) were identified by surface markers, and phosphorylation was measured after cytokine or lipopolysaccharide stimulation. Medical records were reviewed 9-10 years later, comparing RP subjects who developed SSc (SSc+, n = 8) with those who did not (SSc-, n = 17) and healthy controls (HCs, n = 8).
Results: SSc+ patients had significantly higher constitutive pSmad2/3 levels in CD4+ T cells than SSc- or HCs (p = 0.005 and p = 0.034). SSc+ and SSc- had higher stimulated pSTAT3(pY705) levels in CD4+ T cells than HCs (p = 0.001 and p = 0.026). SSc+ had higher stimulated pSTAT6 levels in CD4+ T cells compared with HCs (p = 0.017) and in CD19+ B cells compared with SSc- and HCs (p = 0.006 and p < 0.001). SSc+ had higher stimulated pSTAT4 levels in CD4+ T cells compared with SSc- and HCs (p = 0.004 and p = 0.037) and in CD8+ T cells compared with SSc- (p = 0.007). No significant differences were found in pNF-κB and pSTAT3(pS727) levels.
Conclusion: The results give insights into the pathogenesis of SSc. Smad2/3, STAT3(pY705), STAT6, and STAT4 pathways may serve as novel SSc biomarkers.
{"title":"Signalling profile of circulating leucocytes of subjects with Raynaud's phenomenon in relation to systemic sclerosis: a pilot study.","authors":"P Parmanne, A Kuuliala, A Häme, R Luosujärvi, M Leirisalo-Repo, K Kuuliala","doi":"10.1080/03009742.2025.2562676","DOIUrl":"https://doi.org/10.1080/03009742.2025.2562676","url":null,"abstract":"<p><strong>Objective: </strong>Raynaud's phenomenon (RP) is a common symptom and may be an early sign of systemic sclerosis (SSc). To identify biomarkers distinguishing whether RP is associated with definitive SSc, we used phosphospecific flow cytometry to measure phosphorylated (p) signalling molecules [signal transducers and activators of transcription (pSTAT3, pSTAT6, pSTAT4), pSmad2/3, nuclear factor-κB (pNF-κB)] in peripheral blood leucocytes of RP patients undergoing nailfold videocapillaroscopy.</p><p><strong>Method: </strong>Leucocyte subsets (CD14<sup>+</sup> monocytes, CD4<sup>+</sup> and CD8<sup>+</sup> T cells, CD19<sup>+</sup> B cells) were identified by surface markers, and phosphorylation was measured after cytokine or lipopolysaccharide stimulation. Medical records were reviewed 9-10 years later, comparing RP subjects who developed SSc (SSc<sup>+</sup>, n = 8) with those who did not (SSc<sup>-</sup>, n = 17) and healthy controls (HCs, n = 8).</p><p><strong>Results: </strong>SSc<sup>+</sup> patients had significantly higher constitutive pSmad2/3 levels in CD4<sup>+</sup> T cells than SSc<sup>-</sup> or HCs (p = 0.005 and p = 0.034). SSc<sup>+</sup> and SSc<sup>-</sup> had higher stimulated pSTAT3(pY705) levels in CD4<sup>+</sup> T cells than HCs (p = 0.001 and p = 0.026). SSc<sup>+</sup> had higher stimulated pSTAT6 levels in CD4<sup>+</sup> T cells compared with HCs (p = 0.017) and in CD19<sup>+</sup> B cells compared with SSc<sup>-</sup> and HCs (p = 0.006 and p < 0.001). SSc<sup>+</sup> had higher stimulated pSTAT4 levels in CD4<sup>+</sup> T cells compared with SSc<sup>-</sup> and HCs (p = 0.004 and p = 0.037) and in CD8<sup>+</sup> T cells compared with SSc<sup>-</sup> (p = 0.007). No significant differences were found in pNF-κB and pSTAT3(pS727) levels.</p><p><strong>Conclusion: </strong>The results give insights into the pathogenesis of SSc. Smad2/3, STAT3(pY705), STAT6, and STAT4 pathways may serve as novel SSc biomarkers.</p>","PeriodicalId":21424,"journal":{"name":"Scandinavian Journal of Rheumatology","volume":" ","pages":"1-8"},"PeriodicalIF":2.1,"publicationDate":"2025-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145439019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}